Irinotecan (CPT-11)

TERMINATED · PHASE2 · Small Cell Lung Cancer

Unknown stopping reason

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.